Koike Minako, Takei Takashi, Uchida Keiko, Honda Kazuho, Moriyama Takahito, Horita Shigeru, Ogawa Tetsuya, Yoshida Takumi, Tsuchiya Ken, Nitta Kosaku
Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Kidney Center and Department of Pathology II, Tokyo Women's Medical University, Tokyo, Japan.
Clin Exp Nephrol. 2008 Aug;12(4):250-255. doi: 10.1007/s10157-008-0036-7. Epub 2008 Feb 21.
BACKGROUND/AIM: No accepted therapy has been established for progressive IgA nephropathy (IgAN). The purpose of the present study was to assess low-dose steroid therapy in the treatment of patients with IgAN.
A prospective trial of low-dose steroid therapy was performed in patients with IgAN with mild histological activities. Twenty-four patients in the steroid group and 24 patients in the control group were included in this study. The initial dose of prednisolone was 0.4 mg/kgBW/day (20-30 mg/day), gradually tapered to 5-10 mg/day over 24 months. The patients with mild active inflammatory lesions were treated with prednisolone. The patients assigned to the control group were treated with dipyridamole or zilazep hydrochloride in a dose of 150 or 300 mg/day.
In all of the patients studied, serum creatinine levels did not significantly change over 24 months. However, daily proteinuria significantly reduced after 24 months of steroid therapy (0.97 +/- 0.75 vs. 0.31 +/- 0.51 g/day, P = 0.0012), even if did not change after 24 months of anti-platelet drugs (0.89 +/- 0.49 vs. 0.68 +/- 0.69 g/day, P = 0.2289), respectively. In addition, the grade of hematuria significantly reduced after 24 months of steroid therapy (35.6 +/- 36.3 RBC/HPF vs. 13.7 +/- 28.4 RBC/HPF, P = 0.0249) and 24 months of anti-platelet drugs (30.1 +/- 37.1 RBC/HPF vs. 12.4 +/- 20.3 RBC/HPF, P = 0.0465), respectively. Systolic and diastolic blood pressures did not significantly change during treatment with steroid or anti-platelet drugs. Vascular changes (0.63 +/- 0.73) in the steroid group were lower than those (1.08 +/- 0.88) in the control group (P = 0.008).
Our data suggested that low-dose steroid therapy for IgAN patients with mild inflammatory lesions could reduce the amount of urinary protein excretion and prevent deterioration of renal function, provided the histological findings in the renal biopsies showed mild vascular lesions.
背景/目的:对于进行性IgA肾病(IgAN),尚未确立被广泛接受的治疗方法。本研究的目的是评估低剂量类固醇疗法对IgAN患者的治疗效果。
对具有轻度组织学活动的IgAN患者进行低剂量类固醇疗法的前瞻性试验。本研究纳入了类固醇组的24例患者和对照组的24例患者。泼尼松龙的初始剂量为0.4mg/kg体重/天(20 - 30mg/天),在24个月内逐渐减至5 - 10mg/天。对具有轻度活动性炎性病变的患者采用泼尼松龙治疗。分配到对照组的患者采用双嘧达莫或盐酸齐拉西泮治疗,剂量为150或300mg/天。
在所有研究患者中,血清肌酐水平在24个月内未发生显著变化。然而,类固醇治疗24个月后,每日蛋白尿显著减少(0.97±0.75 vs. 0.31±0.51g/天,P = 0.0012),而抗血小板药物治疗24个月后蛋白尿未发生变化(0.89±0.49 vs. 0.68±0.69g/天,P = 0.2289)。此外,类固醇治疗24个月后血尿程度显著降低(35.6±36.3个红细胞/高倍视野 vs. 13.7±28.4个红细胞/高倍视野,P = 0.0249),抗血小板药物治疗24个月后血尿程度也显著降低(30.1±37.1个红细胞/高倍视野 vs. 12.4±20.3个红细胞/高倍视野,P = 0.0465)。在类固醇或抗血小板药物治疗期间,收缩压和舒张压均未发生显著变化。类固醇组的血管变化(0.63±0.73)低于对照组(1.08±0.88)(P = 0.008)。
我们的数据表明,对于具有轻度炎性病变的IgAN患者,低剂量类固醇疗法可减少尿蛋白排泄量并预防肾功能恶化,前提是肾活检的组织学结果显示为轻度血管病变。